Exclusive: Life Sciences Investor Briefing - Destiny Pharma #DEST, Shield #STX & Open Orphan #ORPH Watch Now

BioPharma Credit Says Lexicon-Sanofi Settlement Enhances Loan Assets

Wed, 11th Sep 2019 18:19

(Alliance News) - BioPharma Credit PLC said Wednesday the termination of an alliance between Sanofi SA and Lexicon Pharmaceuticals Inc enhances the collateral value behind its loan to Lexicon.

BioPharma - a pharmaceutical debt investor - funded USD124.5 million of a USD150 million loan to Lexicon, which matures in 2022. This loan is secured on "substantially all" of the assets of Lexicon, including its rights to the Zynquista diabetes drug.

On Monday, Sanofi and Lexicon terminated an alliance for the development and commercialisation of Zynquista - the brand name of sotagliflozin - as well as a settlement of disputes.

Under the deal, Lexicon regained all rights to Zynquista and assumed all responsbility for development and commercialisation of the type one and type two diabetes treatment. Sanofi also paid Lexicon USD260 million.

On Wednesday, BioPharma said it believed that the "settlement announced by Lexicon further enhances the value of the collateral supporting the loan" issued by BioPharma to Lexicon.

Shares in BioPharma closed 0.5% higher at USD1.02 in London on Wednesday.

Related Shares

More News

BioPharma Credit To Invest USD150 Million In OptiNose US

(Alliance News) - BioPharma Credit PLC on Friday said it, alongside subsidiary BioPharma Credit Investments V Master LP, has agreed to buy senior secured notes of OptiNose US Inc for up to USD150

13 Sep 19 11:30

BioPharma Credit Says Lexicon-Sanofi Settlement Enhances Loan Assets

(Alliance News) - BioPharma Credit PLC said Wednesday the termination of an alliance between Sanofi SA and Lexicon Pharmaceuticals Inc enhances the collateral value behind its loan to - a debt - a

11 Sep 19 18:19

BioPharma Credit Net Assets Rise On Tesaro Sale To GlaxoSmithKline

(Alliance News) - BioPharma Credit PLC on Wednesday reported a rise in net assets over the first half following the acquisition of a portfolio company by pharma giant GlaxoSmithKline PLC.At

4 Sep 19 12:50

BioPharma Credit Declares Unchanged Second Quarter Dividend

(Alliance News) - Life science debt investor BioPharma Credit PLC declared a flat second quarter interim dividend.The USD0.02 per share dividend for the period ended June 30 is also flat is

2 Aug 19 17:31

Login to your account

Don't have an account? Click here to register.